HLB Pep Co., Ltd.
Research HLB Pep Co., Ltd. (196300.KQ) on Bullrun: market cap KRW 40.51B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker196300.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorBasic Materials
- IndustryChemicals
- CurrencyKRW
- Market capKRW 40.51B
- Financial periodQ2 2026
- RevenueKRW 1.26B
- Net income-KRW 735.38M
- Free cash flow-KRW 150.42M
- Gross margin-7.1%
Valuation Snapshot
latest market cap is KRW 40.51B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 40.51B | n/a | n/a | n/a |
Dividend history
About HLB Pep Co., Ltd.
HLB Pep Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It offers GMP, generic, custom, and catalog peptides, as well as offers other services. The company develops AGM-130, which is in Phase I for the treatment of triple negative breast cancer. In addition, its pre-clinical products include AGM-331 targeted for anti-cancer therapy; AGM-380 indicated for the treatment of viral infection;
Related stock research
Other Basic Materials stocks
Frequently asked questions
What is HLB Pep Co., Ltd.'s market cap?
HLB Pep Co., Ltd.'s market capitalization is KRW 40.51B.
What does HLB Pep Co., Ltd. do?
HLB Pep Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It offers GMP, generic, custom, and catalog peptides, as well as offers other services. The company develops AGM-130, which is in Phase I for the treatment of triple negative breast cancer. In addition, its pre-clinical products include AGM-331 targeted for anti-cancer therapy; AGM-380 indicated for the treatment of viral infection; and AGM-290 indicated for the treatment of infections caused by multidrug resistant bacteria.